Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm? (Q34146983)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

C H Rojas-Fernandez

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

D D Allen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

C MacKnight

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

74-102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

Review: delusions in dementia

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Psychiatric symptoms in patients with dementia predict the later development of behavioural abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Factors associated with psychotic symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Behaviour changes in dementia. 2: Are there behavioural syndromes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Why do frontal lobe symptoms predominate in vascular dementia with lacunes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

The Pittsburgh Agitation Scale: A User-Friendly Instrument for Rating Agitation in Dementia Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Cornell Scale for Depression in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

The spectrum of behavioral changes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Psychotic symptoms and physically aggressive behavior in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Natural history of aggressive behaviour in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Predictors of mortality in nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Predictors of mortality in patients with Alzheimer's disease living in nursing homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Placement of dementia sufferers in residential and nursing home care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Nursing home placement is related to dementia progression: experience from a clinical trial. Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Prevalence and impact of caregiving: a detailed comparison between dementia and nondementia caregivers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Neuropathologic and neurochemical correlates of psychosis in primary dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Platelet tritiated imipramine binding and MAO activity in Alzheimer's disease patients with agitation and delusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Evidence of a Monoaminergic-Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Neurochemical Correlates of Major Depression in Primary Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Post-mortem examination of dopaminergic parameters in Alzheimer's disease: relationship to noncognitive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Possible neurotransmitter basis of behavioral changes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

The neuropathology of aminergic nuclei in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Platelet 3H-imipramine binding distinguishes depression from Alzheimer dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Increased activity of surviving locus ceruleus neurons in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Autonomic dysfunction in patients with dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

New atypical antipsychotics. Experience and utility in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Drug-induced cognition disorders in the elderly: incidence, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Benzodiazepine use and cognitive function among community-dwelling elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Psychotropic drugs and falls: new evidence pertaining to serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Newer psychotropic medication use in nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Pharmacology of Antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Citalopram in the treatment of depression and other potential uses in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A metaanalysis of controlled trials of neuroleptic treatment in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Pharmacokinetics of haloperidol: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Pharmacogenetics of classical and new antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Systematic review and guide to selection of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Selective serotonin reuptake inhibitors in older patients. A tolerability perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Clozapine in Older Patients With Psychosis and Behavioral Disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Risperidone treatment of behavioral disturbances in outpatients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Behavioural problems associated with dementia: the role of newer antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Serotonin Reuptake Inhibitors for the Treatment of Coexisting Depression and Psychosis in Dementia of the Alzheimer Type

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

21 January 2018

Frontotemporal Dementia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Drug interactions of clinical significance with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Effects of trazodone on aggressive behavior in seven patients with organic mental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A naturalistic study of trazodone in the treatment of behavioral complications of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Comprehensive review of the psychiatric uses of valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

An open trial of valproate for agitation in geriatric neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Gabapentin for behavioral agitation in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Effectiveness of gabapentin for the treatment of behavioral disorders in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Cholinesterase inhibitors: A new class of psychotropic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Topographical distribution of neurochemical changes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Lewy bodies and response to tacrine in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Dementia with Lewy bodies: response of delirium-like features to donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Dementia with Lewy bodies: review and pharmacotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Corticobasal ganglionic degeneration with Balint's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Propranolol for the control of belligerent behavior following acute brain damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Therapeutic use of propranolol for intermittent explosive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Metoprolol for intermittent explosive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Treating behavioural and psychological signs in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Physical aggression in dementia patients and its relationship to depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Antipsychotic agents in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Behavioral Syndromes in Alzheimer’s Disease: Description and Correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.1.74.34437

10.1592/PHCO.21.1.74.34437

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11191740%20AND%20SRC:MED&resulttype=core&format=json

release_d2bcohxuirdrngxlrfxiuycdfy

4 November 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d2bcohxuirdrngxlrfxiuycdfy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference